Clinical Trials for Other Solid Tumor

An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial includes adults with locally advanced or metastatic solid tumors characterized by the KRAS G12D mutation, evaluating the investigational drug ASP4396, which targets this mutation to determine safety, tolerability, and optimal dosing.

ClinicalTrials.gov ID: NCT06364696

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The TRIDENT-1 trial involves administering repotrectinib, a small molecule inhibitor targeting ALK, ROS1, and NTRK kinases, to adult patients with advanced solid tumors, including NSCLC, that harbor these specific gene rearrangements, evaluating both treatment-naïve and pre-treated patients to assess safety, optimum dosing, and efficacy.

ClinicalTrials.gov ID: NCT03093116

Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the efficacy and safety of an immunotherapy-based treatment regimen with pembrolizumab, alone or combined with chemotherapy, for patients with metastatic or unresectable non-small cell lung cancer with an ECOG performance status of 0-2, comparing outcomes between PS2 and PS0-1 groups. It excludes patients with targetable mutations or severe comorbid conditions.

ClinicalTrials.gov ID: NCT04253964

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial is evaluating the safety and preliminary efficacy of combining sarilumab, an IL-6 receptor antibody, with cemiplimab, an anti-PD1 antibody, in patients with locally advanced or metastatic non-squamous non-small cell lung cancer harboring EGFR or LKB1 mutations, who may have received up to three prior therapies.

ClinicalTrials.gov ID: NCT05704634

A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates cabozantinib, an oral tyrosine kinase inhibitor, in adult patients with advanced non-small cell lung cancer exhibiting RET, ROS1, or NTRK fusions, or increased MET or AXL activity, to assess its efficacy in tumor reduction.

ClinicalTrials.gov ID: NCT01639508

A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial involves patients with recurrent, metastatic solid tumors expressing HHLA2, including specific cancers like non-small cell lung carcinoma, who are treated with NPX267, a novel monoclonal antibody targeting KIR3DL3 to reactivate immune responses in tumors.

ClinicalTrials.gov ID: NCT05958199

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets patients with PD-L1-negative, advanced non-small cell lung cancer lacking actionable EGFR, ALK, or ROS1 mutations, comparing the efficacy of standard immunotherapy (nivolumab targeting PD-1 and ipilimumab targeting CTLA-4) with or without chemotherapy, versus adding radiation therapy to these treatments.

ClinicalTrials.gov ID: NCT04929041

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced NSCLC, specifically with EGFR exon 20 insertion mutations, who have received prior therapy, assessing the efficacy of osimertinib, a third-generation EGFR-tyrosine kinase inhibitor targeting these mutations.

ClinicalTrials.gov ID: NCT03191149

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves untreated patients with advanced KRAS-mutated non-small cell lung cancer (NSCLC) receiving a pooled mutant KRAS-targeted long peptide vaccine with poly-ICLC adjuvant, combined with nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) to evaluate safety, feasibility, and efficacy. Eligible patients must have specific KRAS mutations and measurable disease.

ClinicalTrials.gov ID: NCT05254184

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This clinical trial evaluates the safety and efficacy of the investigational drug NEO212, a novel conjugate of temozolomide and perillyl alcohol with enhanced brain penetration, in adults with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, or uncontrolled brain metastases from select solid tumors, including combinations with standard treatments like pembrolizumab or ipilimumab.

ClinicalTrials.gov ID: NCT06047379